AcuraBio specifically biomanufactures via microbial systems because they offer many advantages such as lower generation time, rapid growth rates, and lower media costs.
AcuraBio can use Saccharomyces cerevisiae for yeast fermentation to produce biopharmaceuticals. S. cerevisiae is advantageous as a cell factory to produce biopharmaceuticals because the organism is well-understood, which provides an extensive knowledge base for further engineering.
We also offer clients the ability to produce biopharmaceuticals using Pichia pastoris, a robust yeast expression system that produces high levels of recombinant proteins. The Pichia system is stable, durable, and cost-effective. Pichia grows on simple media and secretes low amounts of endogenous protein, making it easier to recover and purify the desired recombinant protein from the cell supernatant.
Other organisms used for recombinant protein production include E. coli, B. subtilis, and Corynebacterium.
We offer a full suite of manufacturing both whole cell preparations, recombinant products from microbial hosts, and naturally produced cellular macromolecules such as carbohydrates and anaerobic fermentation products. Processing can be undertaken under GMP or non GMP as needed.
Our manufacturing processes can be operated in numerous modes (e.g., batch, fed batch, and perfusion) and we offer a full suite of manufacturing including whole cell preparations, recombinant products from microbial hosts, and naturally produced cellular products. Processing can be carried out as either non-GMP or GMP.
Capabilities:
- Master and working cell bank preparation, validation, and storage
- Fermentation and subsequent downstream purification
- Up and downscale work up optimization
- Downstream processing optimization and development
